Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | ADK | P55263 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL67017 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL28722063 | 0.78 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2CYP19A1NISCHMTOR | |
| SCHEMBL3434072 | 0.77 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2CYP19A1NISCH | |
| SCHEMBL5380824 | 0.76 | — | — | |
| SCHEMBL22482971 | 0.76 | — | — | |
| SCHEMBL19928167 | 0.76 | — | — | |
| SCHEMBL3403575 | 0.76 | — | — | |
| SCHEMBL7838270 | 0.76 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2CYP19A1NISCHMTOR | |
| Hydrochloric Acid SCHEMBL31019202 | 0.74 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2CYP19A1NISCHMTOR | |
| SCHEMBL9328500 | 0.74 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2CYP19A1NISCHMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-8129389-B2 | Substituted oxindole derivatives, medicaments containing the latter and use thereof | ABBOTT GMBH & CO. KG (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBOTT GMBH & CO. KG | 2009-07-23 | — | — | US | disclosed |
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | ABBOTT GMBH & CO. KG | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186904-A1 | Substituted Oxindole Derivatives, Medicaments Containing the Latter and Use Thereof | OXTR, AVPR2, AVPR1B | ALDH1A1 1261/4885SMN1; SMN2 3749/4885CYP19A1 362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.